PreludeDx: Derek Maetzold

Feb 07, 2022

PreludeDx has appointed Derek Maetzold to its board of directors. Maetzold founded Castle Biosciences, serving as president, CEO, and a board member since its inception in 2007. He co-invented several Castle technologies and has contributed to the development and commercialization of five diagnostic and prognostic cancer tests.

Prior to Castle, Maetzold spent 24 years in pharma, holding leadership roles at Encysive Pharmaceuticals (acquired by Pfizer), Schering-Plough Corporation (now Merck), Integrated Communications (now FCB Health), Amylin Pharmaceuticals (now owned by AstraZeneca), and Sandoz Pharmaceuticals (now a division of Novartis).

PreludeDx: Derek Maetzold

Vanderbilt Team Reports on Clinical Genetic Testing Patterns Over Two Decades

BioMérieux Confirms Full-Year Growth Guidance as Q1 Sales Rise 14 Percent

Sonrai, Paige Partner to Build AI Interface for Biopharma Researchers and Clinicians

NIH Funding Cut by 40 Percent in Trump Admin's FY2026 Budget Proposal

Illumina Lays off More Than 300 Employees